ALKERMES | ALKS - Ebitda



ALKERMES reported $126.53M in EBITDA for its fiscal quarter ending in June of 2025.


Ebitda Change Date
AbbVie USD 4.4B 2.52B Mar/2025
Acadia Pharmaceuticals USD 35.31M 13.07M Jun/2025
ALKERMES USD 126.53M 105.32M Jun/2025
Amgen USD 3.6B 147M Jun/2025
Biogen USD 1.01B 456.5M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Bristol-Myers Squibb USD 3.27B 1.63B Jun/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Gilead Sciences USD 3.4B 797M Jun/2025
Ionis Pharmaceuticals USD 150.23M 291.7M Jun/2025
J&J USD 7.88B 1.76B Mar/2025
Malin Corporation EUR -1100000 200K Dec/2024
Merck USD 7.74B 625M Mar/2025
Neurocrine Biosciences USD 152.9M 121.6M Jun/2025
Otsuka Holdings JPY 134.59B 9.43B Jun/2025
Pfizer USD 5.32B 889M Jun/2025
Regeneron Pharmaceuticals USD 1.66B 926.5M Jun/2025
Vertex Pharmaceuticals USD 1.34B 556.6M Jun/2025